Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC)

作者： BI Mattar , Y. Li , AA Forastiere , W Flood , BA Burtness

DOI:

关键词: Head and neck cancer 、 Antibody 、 Oncology 、 Metastatic/Recurrent 、 In patient 、 Placebo 、 Cisplatin 、 Medicine 、 Epidermal growth factor 、 Internal medicine